imiquimod has been researched along with cyclosporine in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 2 (28.57) | 24.3611 |
| 2020's | 4 (57.14) | 2.80 |
| Authors | Studies |
|---|---|
| Dranchak, PK; Huang, R; Inglese, J; Lamy, L; Oliphant, E; Queme, B; Tao, D; Wang, Y; Xia, M | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Haustein, UF; Paasch, U | 1 |
| Kim, CH; Kim, JY; Lee, AY | 1 |
| Du, Z; Li, N; Lu, C; Wu, D; Yuan, X; Zhang, M; Zhu, W | 1 |
| Chao, YH; Chen, HH; Huang, WC; Lee, PY; Lin, CC; Tung, YT | 1 |
| Bhardwaj, P; Gupta, R; Pandey, S; Ramchandra Patil, P; Tripathi, P | 1 |
7 other study(ies) available for imiquimod and cyclosporine
| Article | Year |
|---|---|
In vivo quantitative high-throughput screening for drug discovery and comparative toxicology.
Topics: Animals; Caenorhabditis elegans; Drug Discovery; High-Throughput Screening Assays; Humans; Proteomics; Small Molecule Libraries | 2023 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Aggressive undifferentiated squamous cell carcinoma in an immunosuppressed patient after kidney transplantation.
Topics: Acitretin; Adjuvants, Immunologic; Administration, Oral; Aminoquinolines; Antineoplastic Agents; Carcinoma, Squamous Cell; Counseling; Cyclosporine; Follow-Up Studies; Humans; Imiquimod; Immunocompromised Host; Immunosuppressive Agents; Keratolytic Agents; Keratosis; Kidney Transplantation; Male; Middle Aged; Ointments; Skin; Skin Neoplasms; Sunscreening Agents; Time Factors | 2005 |
Therapeutic and immunomodulatory effects of glucosamine in combination with low-dose cyclosporine a in a murine model of imiquimod-induced psoriasis.
Topics: Aminoquinolines; Animals; Cyclosporine; Dermatitis; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Glucosamine; Imiquimod; Immunomodulation; Mice; Mice, Inbred C57BL; Organ Size; Psoriasis; Spleen; T-Lymphocytes, Regulatory | 2015 |
Taxifolin attenuates IMQ-induced murine psoriasis-like dermatitis by regulating T helper cell responses via Notch1 and JAK2/STAT3 signal pathways.
Topics: Animals; Cell Line; Cell Proliferation; Cyclosporine; Cytokines; Dermatitis; Humans; Imiquimod; Inflammation; Janus Kinase 2; Keratinocytes; Lipopolysaccharides; Male; Mice; Mice, Inbred BALB C; Models, Animal; Psoriasis; Quercetin; Receptor, Notch1; Signal Transduction; Skin; STAT3 Transcription Factor; T-Lymphocytes; Transcription Factors | 2020 |
Combination Therapy of Acarbose and Cyclosporine a Ameliorates Imiquimod-Induced Psoriasis-Like Dermatitis in Mice.
Topics: Acarbose; Animals; Anti-Inflammatory Agents; Cyclosporine; Cytokines; Disease Models, Animal; Drug Therapy, Combination; Gene Expression Regulation; Humans; Imiquimod; Male; Mice; Psoriasis; T-Lymphocytes, Regulatory; Tumor Necrosis Factor-alpha | 2020 |
Cyclosporine and Pentoxifylline laden tailored niosomes for the effective management of psoriasis: In-vitro optimization, Ex-vivo and animal study.
Topics: Animals; Cholesterol; Cyclosporine; Imiquimod; Liposomes; Mice; Particle Size; Pentoxifylline; Polysorbates; Psoriasis; Surface-Active Agents | 2022 |